Antibody-based cancer therapy

Bibliography

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7
   PubMed Web of Science ®Google Scholar
• Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 2006;20(3):585-612
   PubMed Web of Science ®Google Scholar
• Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005;24(4):487-99
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26(4 Suppl 12):78-83
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18(17):3135-43
   PubMed Web of Science ®Google Scholar
• Saleh MN, Khazaeli MB, Grizzle WE, et al. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res 1993;53(19):4555-62
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules, particles, and cells in solid tumors. Ann Rev Biomed Eng 1999;1:241-63
   PubMed Web of Science ®Google Scholar
• Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31(7):1191-8
   PubMed Web of Science ®Google Scholar
• Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61(12):4750-5
   PubMed Web of Science ®Google Scholar
• Blumenthal RD, Fand I, Sharkey RM, et al. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother 1991;33(6):351-8
   PubMed Web of Science ®Google Scholar
• Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006;58(5-6):640-56
   PubMed Web of Science ®Google Scholar
• Brown VI, Shah N, Smith R, et al. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor. DNA Cell Biol 1994;13(2):193-209
   PubMed Web of Science ®Google Scholar
• Drebin JA, Link VC, Stern DF, et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41(3):697-706
   PubMed Web of Science ®Google Scholar
• Katsumata M, Okudaira T, Samanta A, et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1995;1(7):644-8
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9(3):1165-72
   PubMed Web of Science ®Google Scholar
• Sarup JC, Johnson RM, King KL, et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1(2):72-82
   PubMedGoogle Scholar
• Shawver LK, Mann E, Elliger SS, et al. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Cancer Res 1994;54(5):1367-73
   PubMed Web of Science ®Google Scholar
• Stancovski I, Hurwitz E, Leitner O, et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991;88(19):8691-5
   PubMed Web of Science ®Google Scholar
• Patel D, Lahiji A, Patel S, et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 2007;27(5A):3355-66
   PubMed Web of Science ®Google Scholar
• Arnoletti JP, Buchsbaum DJ, Huang ZQ, et al. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J Gastrointest Surg 2004;8(8):960-9;discussion 9-70
   PubMed Web of Science ®Google Scholar
• Alfonso-Perez M, Lopez-Giral S, Quintana NE, et al. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 2006;79(6):1157-65
   PubMed Web of Science ®Google Scholar
• Xu F, Lupu R, Rodriguez GC, et al. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 1993;53(3):401-8
   PubMed Web of Science ®Google Scholar
• Tagliabue E, Centis F, Campiglio M, et al. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer 1991;47(6):933-7
   PubMed Web of Science ®Google Scholar
• Park BW, O'Rourke DM, Wang Q, et al. Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases. Proc Natl Acad Sci USA 1999;96(11):6434-8
   PubMed Web of Science ®Google Scholar
• Scott GK, Dodson JM, Montgomery PA, et al. p185HER2 signal transduction in breast cancer cells. J Biol Chem 1991;266(22):14300-5
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 2005;5(Suppl 1):S19-27
   PubMed Web of Science ®Google Scholar
• Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41(2):107-27
   PubMed Web of Science ®Google Scholar
• Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005;12(2):105-10
   PubMedGoogle Scholar
• Kopnin BP. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry (Mosc) 2000;65(1):2-27
   PubMed Web of Science ®Google Scholar
• Hung H. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. Mol Cancer Ther 2007;6(8):2149-57
   PubMed Web of Science ®Google Scholar
• Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and – independent mechanisms. J Radiat Res (Tokyo) 2006;47(2):183-96
   PubMed Web of Science ®Google Scholar
• Grothey A. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. Semin Oncol 2006;33(5 Suppl 10):S41-9
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328-35
   PubMed Web of Science ®Google Scholar
• Kanai T, Konno H, Tanaka T, et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998;77(6):933-6
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
   PubMed Web of Science ®Google Scholar
• Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59(14):3374-8
   PubMed Web of Science ®Google Scholar
• de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005;69(Suppl 3):46-56
   PubMed Web of Science ®Google Scholar
• D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23(28):7135-42
   PubMed Web of Science ®Google Scholar
• Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005;19(11):1993-5
   PubMed Web of Science ®Google Scholar
• Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(Suppl 3):25-33
   PubMed Web of Science ®Google Scholar
• Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16(5):1788-94
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001;40(1):17-24
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
   PubMed Web of Science ®Google Scholar
• Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-68
   PubMed Web of Science ®Google Scholar
• Le XF, Claret FX, Lammayot A, et al. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 2003;278(26):23441-50
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82
   PubMed Web of Science ®Google Scholar
• Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 1994;15(1):42-52
   PubMed Web of Science ®Google Scholar
• Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71(8):2454-60
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7(4):301-11
   PubMed Web of Science ®Google Scholar
• Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005;16(1):7-15
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25(33):5225-32
   PubMed Web of Science ®Google Scholar
• Panikkar RP, Astsaturov I, Langer CJ. The emerging role of cetuximab in head and neck cancer: a 2007 perspective. Cancer Invest 2008;26(1):96-103
   PubMed Web of Science ®Google Scholar
• Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69(2):584-91
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
   PubMed Web of Science ®Google Scholar
• Marinkovic M, Milosevic D, Tomasevic Z, Jelic S. The changes of serum immunoglobulins in patients treated by a combination of anti-CD20 monoclonal antibody rituximab plus chlorambucil for low-grade non-Hodgkin's lymphoma. J Buon 2002;7(4):331-5
   PubMedGoogle Scholar
• Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35(3):118-27
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16(10):3257-63
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
   PubMed Web of Science ®Google Scholar
• Amgen I. Amgen discontinues Vectibix™ treatment in PACCE trial evaluating VECTIBIX™ as part of triple combination regimen (press release). In: Amgen I, editor. Thousand Oaks, CA; 2007
   Google Scholar
• Reff ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 2001;40(1):25-35
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23(9):1137-46
   PubMed Web of Science ®Google Scholar
• Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999;26(5 Suppl 14):58-65
   PubMed Web of Science ®Google Scholar
• Prestwich WV, Nunes J, Kwok CS. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med 1989;30(6):1036-46
   PubMed Web of Science ®Google Scholar
• Denardo GL, Denardo SJ, Kukis DL, et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res 1998;18(4B):2779-88
   PubMed Web of Science ®Google Scholar
• DeNardo GL, DeNardo SJ, Lamborn KR, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13(4):239-54
   PubMed Web of Science ®Google Scholar
• Caron PC, Schwartz MA, Co MS, et al. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer 1994;73(Suppl 3):1049-56
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111;In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999;5(Suppl 10):s3292-303
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17(12):3793-803
   PubMed Web of Science ®Google Scholar
• Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61(2):203-12
   PubMed Web of Science ®Google Scholar
• Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77(10):699-712
   PubMed Web of Science ®Google Scholar
• Negri DR, Tosi E, Valota O, et al. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer 1995;72(4):928-33
   PubMed Web of Science ®Google Scholar
• Canevari S, Mezzanzanica D, Mazzoni A, et al. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 1995;4(5):423-7
   PubMedGoogle Scholar
• Lum LG, Rathore R, Cummings F, et al. Phase I/II study of treatment of stage IV breast cancer with OKT3 × trastuzumab-armed activated T cells. Clin Breast Cancer 2003;4(3):212-7
   PubMedGoogle Scholar
• Davol PA, Smith JA, Kouttab N, et al. Anti-CD3 × anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Clin Prostate Cancer 2004;3(2):112-21
   PubMedGoogle Scholar
• Gall JM, Davol PA, Grabert RC, et al. T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005;33(4):452-9
   PubMed Web of Science ®Google Scholar
• Reusch U, Sundaram M, Davol PA, et al. Anti-CD3 × anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 2006;12(1):183-90
   PubMed Web of Science ®Google Scholar
• Lum LG, Davol PA, Lee RJ. The new face of bispecific antibodies: targeting cancer and much more. Exp Hematol 2006;34(1):1-6
   PubMed Web of Science ®Google Scholar
• Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 2001;49(7):911-7
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83(2):261-6
   PubMed Web of Science ®Google Scholar
• Jaeger M, Stroehlein M, Schoberth A, et al. Immunotherapy with the trifunctional antibody removal leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study. J Clin Oncol 2004;23(Suppl):2504
   Google Scholar
• Stroehlein M, Jaeger M, Lindhofer H, et al. Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. J Clin Oncol 2004;23(Suppl):2532
   Google Scholar
• Sebastian M, Passlick B, Friccius-Quecke H, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study. Cancer Immunol Immunother 2007;56(10):1637-44
   PubMed Web of Science ®Google Scholar
• Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995;155(1):219-25
   PubMed Web of Science ®Google Scholar
• Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163(3):1246-52
   PubMed Web of Science ®Google Scholar
• Kiewe P, Hasmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12(10):3085-91
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7(2):95-106
   PubMed Web of Science ®Google Scholar
• Goodwin RG, Din WS, Davis-Smith T, et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993;23(10):2631-41
   PubMed Web of Science ®Google Scholar
• Sica G, Chen L. Modulation of the immune response through 4-1BB. Adv Exp Med Biol 2000;465:355-62
   PubMed Web of Science ®Google Scholar
• Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Ann Rev Immunol 2006;24:65-97
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;37:611-8
   Google Scholar
• Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18(2):206-13
   PubMed Web of Science ®Google Scholar
• Hodge JW, Chakraborty M, Kudo-Saito C, et al. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174(10):5994-6004
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734-6
   PubMed Web of Science ®Google Scholar
• Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res 1999;59(20):5106-11
   PubMed Web of Science ®Google Scholar
• Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24(15):2283-9
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21(21):3940-7
   PubMed Web of Science ®Google Scholar
• Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23(3):474-81
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94(2):259-67
   PubMed Web of Science ®Google Scholar
• Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007;13(17):5133-43
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Storrer CE, Shriver CD, et al. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 2006;13(8):1085-98
   PubMed Web of Science ®Google Scholar
• Gerritsen W, Eertwegh A, De Gruijl T, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone refractory prostate cancer (mHRPC) [abstract]. J Clin Oncol 2006;24(18S Pt 1):2500
   Google Scholar
• Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;1212:1005-16
   Google Scholar